Experience of Using the Complex Antioxidant - Vitamin’ in Post-COVID Asthenia
The result of the pandemic of coronavirus infection caused by the SARS-CoV-2 virus has become a new problem for healthcare - postcovid syndrome. It develops in 10-35% of patients with mild and moderate course and 80% of hospitalized patients with severe COVID-19. The diversity of the clinical picture makes it difficult to diagnose, but the most significant are asthenic disorders. Objective: to evaluate the efficacy and safety of the combined drugMexiB 6® in patients with asthenic disorders who have undergone COVID-19. Material and methods. An observational prospective study was conducted with the participation of 33 patients (27 (82%) women and 6 (18%) men) aged 22-68 years. Two face-to-face visits were conducted during the study. At the first stage, complaints were collected, anamnesis, anthropometry, a six-minute walking test (6MWT), noninvasive angioscanning, at the second, the dynamics of complaints, the distance in 6MWT and the results of noninvasive angioscanning were evaluated. Patients took the drug MexiB 6® for four weeks between the first and second visits. Results. After taking the drug MexiB 6®, positive dynamics was observed with respect to all subjective symptoms of asthenia. At the same time, the best dynamics was observed for the most pronounced and frequent complaints: memory loss, sleep disturbance, increased fatigue with normal physical and emotional stress. Positive dynamics of the results of subjective assessment of asthenia, anxiety and depression according to the FSS and HADS questionnaires after treatment with MexiB 6® was recorded. According to the results of noninvasive scanning, an increase in the number of individuals with normalization of endothelial function after taking the drug MexiB 6® was registered, the differences are statistically insignificant. After the use of the drug MexiB 6®, a statistically significant increase in the distance in 6MWT in dynamics was revealed, which indicated an improvement in the tolerance of physical activity. Conclusion. Against the background of the use of the drug MexiB 6® for four weeks, there was a statistically significant positive dynamics in relation to all subjective symptoms of post-COVID asthenia, as well as an improvement in exercise tolerance in T6MX. To assess the effect of the drug MexiB 6® on endothelial function in patients who have undergone COVID-19, longer studies involving a larger number of patients are needed.